CN101505676A - Pharmacological, chemical, and topical agent enhancement apparatus and method for using same - Google Patents

Abstract

A method for enhancing pharmacological, chemical, topical, and cosmetic effects comprising applying at least one reactive agent to a target pathway structure (step 101); configuring at least one waveform having at least one waveform parameter (step 102); selecting a value of said at least one waveform parameter of said at least one waveform to maximize at least one of a signal to noise ratio and a Power signal to noise ratio (step 103); in a target pathway structure, using said at least one waveform that maximizes said at least one of a signal to noise ratio and a Power signal to noise ratio in a target pathway structure to which said reactive agent has been applied, to generate an electromagnetic signal (step 104); and coupling said electromagnetic signal to said target pathway structure to modulate said target pathway structure (step 105).

Description

Medicament, chemical and topical agent boosting device and method of use

technical field

The present invention relates to enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents used to treat living tissue, cells and molecules by altering the interaction with the electromagnetic environment of the living tissue, cells and molecules. The invention also relates to methods of modulating cell and tissue growth, repair, maintenance and general behavior through the use of encoded electromagnetic information. In particular, the present invention provides the application of very specific electromagnetic frequency (EMF) signal patterns to one or more body parts through surgical non-invasive active coupling of encoded electromagnetic information. The application of such electromagnetic waveforms in combination with pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant target pathway structures (e.g., cells, organs, tissues and molecules) can be used to enhance the various potency.

Background technique

Most low frequency EMF uses are combined with bone repair and healing applications. As such, EMF waveforms and current orthopedic clinical use of EMF waveforms include relatively low frequency components and are of very low power, resulting in maxima in the range of one microvolt per centimeter (mv/cm) at frequencies below 5 KHz. electric field. The linear physicochemical approach of using electrochemical models of cell membranes to predict the range of EMF waveform patterns for which biological effects can be expected is based on the assumption that cell membranes, especially ions bound to structures in or on cell membranes, are possible EMF targets. Therefore, it is necessary to determine the range of waveform parameters for which induced electric fields can couple electrochemically at the cell surface, for example by using voltage-dependent kinetics. An extension of this linear model to include Lorentz force considerations conclusively demonstrates that the magnetic component of EMF can play an important role in EMF therapy. This leads to ion cyclotron resonance and quantum models of interest in predictions from combined AC and DC magnetic field effects in the very low frequency range.

Pulsed radiofrequency (PRF) signals generated from a continuous sine wave at 27.12 MHz for deep tissue healing are known in the art of diathermy. Pulse succession of diathermy signals was originally published as an electromagnetic field capable of stimulating athermal biological effects in the treatment of infectious diseases. Subsequently, therapeutic applications of PFR for reducing post-traumatic and post-operative pain and edema of soft tissues, wound healing, burn treatment and nerve regeneration were reported. The use of PRF for resolution of traumatic edema has been increasingly used in recent years. Results to date using PRF in animal and clinical studies indicate that edema can be modestly reduced by such electromagnetic stimulation.

The present invention is based on biophysical and animal studies that attribute the effects of cell-to-cell communication on tissue structure sensitivity to induced voltages and associated currents. Estimate whether an EMF signal applied to target pathway structures (such as cells, tissues, organs, and molecules) has thermal noise present at ion binding sites using mathematical analysis of at least one of signal-to-noise ratio (SNR) and power signal-to-noise ratio (power-SNR) above is detectable. Prior art EMF dosimetry does not take into account the dielectric properties of tissue structures, instead the prior art utilizes the properties of isolated cells. By exploiting dielectric properties, reactive coupling of electromagnetic waveforms configured by optimizing the SNR and power SNR mathematical values estimated in the target pathway structure can be enhanced applied to human, animal and plant cells, organs, tissues and molecules Various effects of pharmaceutical, chemical, cosmetic and topical agents. The potentiation results from increased blood flow and modulation of angiogenesis and neovascularization and other enhanced biological effect processes.

Recent clinical use of non-invasive PRF in radiofrequency utilizes bursts of 27.12 MHz sine waves, each burst typically exhibiting a width of 65 microseconds, with approximately 1700 sinusoidal periods per burst, and with varying burst repetition rates.

Broad-spectrum density bursts of electromagnetic waveforms having frequencies in the range of one to one hundred megahertz (MHz) are selectively applied to human, animal, and plant cells, organs, tissues, and molecules, with 1 to 100 per burst 100,000 pulses, and a burst repetition rate of 0.01 to 10,000 hertz (Hz). The voltage amplitude envelope of each burst is a function of random, irregular or other similar variables that effectively provide a broad spectral density within the burst envelope. Variables are defined as mathematical functions that consider signal-to-thermal-noise ratio and power SNR in a particular target pathway structure. Waveforms are designed to regulate living cell growth, status and repair. Specific applications of these signals include, but are not limited to: enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents, preventive and healthcare treatment of organs, muscles, joints, skin and hair, post-surgical and traumatic wound healing, angiogenesis , improved blood perfusion, vasodilation, vasoconstriction, edema reduction, enhanced neovascularization, bone repair, tendon repair, ligament repair, organ regeneration and pain relief. The application of electromagnetic waveforms in conjunction with pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules can be used to enhance the various effects of such compounds.

According to embodiments of the present invention, higher spectral density burst envelopes can be more efficiently coupled to physiologically relevant dielectric pathways, such as cell membrane receptors, ions bound to cellular enzymes, and general transmembrane potential changes. Embodiments according to the present invention increase the number of frequency components transmitted to relevant cellular pathways, resulting in a wider range of biophysical phenomena applicable to known healing mechanisms becoming achievable, including enhanced enzyme activity, growth factor release and cytokine release. By increasing the burst duration and by applying a random or other high spectral density envelope to induce peak electric fields between 10 ^-6 and 10 volts per centimeter (V/cm) and meet the detection capability requirements in terms of SNR or power SNR The pulse group envelope of monopolar or bipolar rectangular or sinusoidal pulses can achieve more effective and greater effects in the biological healing process of soft and hard tissues in humans, animals and plants, resulting in pharmaceutical, chemical Enhancement of the efficacy of cosmetic, cosmetic and topical agents.

The present invention relates to known mechanisms of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules. In particular, the efficacy of these agents depends on the optimal dosage of said agent to achieve the desired target pathway structure, which can be achieved by increased blood flow and enhanced chemical activity catalyzed by an increase in active enzymes during the relevant biochemical cascade. Finish. Electromagnetic fields can increase blood flow and ion binding that affect the activity of the agent. An advantageous consequence of using the present invention is that the dose amount may be reduced due to the enhanced potency of the dose. It is an object of the present invention to provide improved methods for enhancing and facilitating the intended action and improving efficacy and other efficacy of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules .

Another object of the present invention is that by applying a high spectral density voltage envelope as a regulation or burst definition parameter in terms of SNR and power SNR requirements, the power requirements for such bursts of increased duration can be significantly lower than those with Power requirements for shorter bursts of pulses in the same frequency range; this results from a more efficient matching of the frequency components to the relevant cellular/molecular processes. Thus, the advantages of enhanced dosimetry of transport to the relevant dielectric pathways and reduced power requirements are obtained.

Therefore, there is a means to more effectively enhance and facilitate the intended action and improve efficacy and other biological effects of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules and method needs.

Summary of the invention

The present invention relates to enhancing the ability to manipulate living tissues, cells and molecules by providing therapeutic, prophylactic and healthcare devices and methods for non-invasive pulsed electromagnetic therapy to enhance the physiological condition, repair and growth of living tissues in animals, humans and plants Efficacy of pharmaceutical, chemical, cosmetic and topical agents. This beneficial approach operates through the use of electromagnetic devices such as EMF generators and high frequency applicator heads to selectively alter the biological electromagnetic environment associated with the cellular and tissue environment. Embodiments in accordance with the invention include routing magnetic flux to selectable body parts comprising a series of EMF pulses characterized by a minimum width of at least 0.01 microseconds within a burst envelope of Between 1 and 100,000 pulses, wherein the voltage amplitude envelope of said burst is defined by a randomly varying parameter, wherein the instantaneous minimum amplitude differs from the maximum amplitude by less than one ten-thousandth. Further, the repetition rate of such bursts can vary from 0.01 to 10,000 Hz. Mathematically definable parameters that meet the SNR and/or power SNR detectability requirements in the target structure are used to define the burst configuration.

The mathematically defined parameters are chosen by considering the dielectric properties of the target pathway structure and the ratio of the induced electric field amplitude to voltage due to thermal noise or other fundamental cellular activities.

Another object of the present invention is to provide: treatment of living cells and tissues by electromagnetically modulating sensitive tuning processes at cell membranes and at junctional interfaces between cells using waveforms tailored to meet SNR and power SNR detection capability requirements in target pathway structures Methods.

Preferred embodiments according to the present invention utilize a power signal-to-noise ratio (power SNR) approach to configuring bioeffect waveforms, and incorporate miniaturized circuitry and lightweight flexible coils. This advantageously allows devices utilizing the power SNR approach, miniaturized circuitry and lightweight flexible coils to be fully portable and configured to be disposable if desired, and implantable if further desired.

In particular, broad-spectrum density bursts of electromagnetic waveforms configured to achieve maximum signal power within the bandpass of a biological target are selectively applied to target pathway structures (such as tissues) to enhance pharmaceutical, chemical, cosmetic, and Efficacy of topical agents. Waveforms are selected using unique amplitude/power comparisons to thermal noise waveforms in target pathway structures. The signal comprises a pulse train of at least one of sinusoidal, rectangular, irregular and random waveforms, has a frequency capacity in the range of about 0.01 Hz to about 100 MHz at about 1 to 100,000 pulses per second, and has a frequency capacity of from about 0.01 to about Pulse repetition rate of 1000 bursts/second. Peak signal amplitudes at target pathway structures such as organs, cells, tissues, and molecules range from about 1 μV/cm to about 100 μV/cm. Each signal burst envelope may be a stochastic function that provides a means of accommodating the different electromagnetic characteristics of the enhanced biological effect process. Preferred embodiments in accordance with the present invention include bursts of about 0.1 to about 100 milliseconds comprising symmetrical or asymmetric pulses of about 1 to about 200 microseconds repeated within the burst at about 0.1 to about 100 kilohertz. The pulse profile is a modified 1/f function and is applied at a random repetition rate between about 0.1 and about 1000 Hz. A fixed repetition rate between about 0.1 Hz and about 1000 Hz may also be used. An induced electric field from about 0.001 V/cm to about 100 mV/cm is generated. Another embodiment in accordance with the present invention includes high frequency sine wave bursts of about 0.01 milliseconds to about 10 milliseconds, such as 27.12 MHz repeated at about 1 to about 100 bursts per second. An induced electric field from about 0.001 V/cm to about 100 mV/cm is generated. The resulting waveform can be transferred by inductive or capacitive coupling.

Contents of the invention

It is an object of the present invention to provide modulation of the electromagnetic susceptibility tuning process at the cell membrane and at the junctional interface between cells.

Another object of the present invention is to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents by configuring the power spectrum of the waveform with the aid of mathematical simulations, the configuration being optimized to modulate angiogenesis using signal-to-noise ratio (SNR) analysis and neovascularization waveforms, and then couple the configured waveforms using a power generation device such as an ultralight metal coil powered by a waveform configuration device such as a miniaturized circuit.

Another object of the present invention is to use any input waveforms, by estimating the electrical equivalent in any target pathway structure (e.g., molecule, Cells, tissues and organs) to regulate angiogenesis and neovascularization to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents.

Another object of the present invention is to provide a device that incorporates the use of power SNR to control and regulate electromagnetic therapeutic treatments to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents.

Another object of the present invention is to provide the use of electromagnetic fields selected by optimal application to biochemical target pathway structures to achieve modulation of angiogenesis and neovascularization in molecules, cells, tissues and organs, to enhance the efficacy of agents, Methods and devices for efficacy of chemical, cosmetic and topical agents.

Another object of the present invention is to significantly reduce the peak amplitude and shorten the pulse duration by virtue of the power SNR by matching the frequency range in the signal to the frequency response and the sensitivity of the target pathway structure (such as molecules, cells, tissues and organs), thus Modulation of angiogenesis and neovascularization is achieved to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents.

It is a further object of the present invention to provide means for the application of electromagnetic waveforms to be used in conjunction with pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules in order to The biological effect process of such compounds can be enhanced.

A further object of the present invention is to provide a method for enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents for therapeutic, preventive and healthcare purposes.

It is a further object of the present invention to provide methods for treating organs, muscles, joints, skin and hair using EMF in conjunction with pharmaceutical, chemical, cosmetic and topical agents to enhance the efficacy of these agents.

It is a further object of the present invention to provide methods for treating organs, muscles, joints, skin and hair using EMF in conjunction with pharmaceutical, chemical, cosmetic and topical agents to enhance health.

It is a further object of the present invention to provide a method in which the electromagnetic waveform is configured according to the SNR and power SNR detection capability requirements in the target pathway structure.

A further object of the present invention is to provide a method for electromagnetic therapy comprising a broadband, high broad spectral density electromagnetic field.

It is an additional object of the present invention to provide methods for enhancing soft and hard tissue repair by using EMF in combination with pharmaceutical, chemical, cosmetic and topical agents.

It is a further object of the present invention to provide a method for enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents by using electromagnetic therapy to modulate angiogenesis to increase blood flow to disease-affected tissues.

It is an additional object of the present invention to provide methods of increasing blood flow to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents that modulate the viability, growth and differentiation of transplanted cells, tissues and organs.

It is a further object of the present invention to provide methods of treating cardiovascular diseases by modulating angiogenesis and increasing blood flow to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents.

A further object of the present invention is to provide a method of increasing the physiological efficacy of pharmaceutical, chemical, cosmetic and topical agents by increasing microvascular blood perfusion and reducing exudation.

It is a further object of the present invention to provide a method of increasing blood flow to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents for the treatment of bone and hard tissue diseases.

It is a further object of the present invention to provide a method of increasing blood flow to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents used to treat edema and swelling of soft tissues.

It is a further object of the present invention to provide a method of increasing blood flow to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents used to repair damaged soft tissue.

It is a further object of the present invention to provide a method of increasing blood flow to damaged tissue by modulating vasodilation and stimulating neovascularization thereby enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents.

It is a further object of the present invention to provide an electromagnetic therapy device wherein said device operates using reduced power levels.

It is a further object of the present invention to provide an electromagnetic treatment device wherein said device is inexpensive and easily portable and produces reduced electromagnetic interference.

The above and still other objects and advantages of the present invention will become apparent from the brief description of the drawings set forth hereinafter, the detailed description of the invention and the claims appended herewith.

Brief description of the drawings

Preferred embodiments of the present invention are described in more detail below with reference to the accompanying drawings:

Figure 1 is a flowchart of a method for enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents used to treat living tissue, cells and molecules according to an embodiment of the present invention;

2 is a view of a control circuit and an electric coil applied to a knee joint according to a preferred embodiment of the present invention;

Fig. 3 is a structural diagram of a miniaturized circuit according to a preferred embodiment of the present invention;

Figure 4A is a line drawing of a metal coil such as an inductor according to a preferred embodiment of the present invention:

Figure 4B is a line drawing of a flexible magnetic metal wire according to a preferred embodiment of the present invention;

Figure 5 depicts waveforms delivered to target pathway structures such as molecules, cells, tissues or organs according to a preferred embodiment of the invention;

Figure 6 is a view of a positioning device such as a wrist support according to a preferred embodiment of the present invention;

Figure 7 is a view of a positioning device such as a mattress pad according to a preferred embodiment of the present invention;

Figure 8 is a graph showing the effect of increasing burst duration according to an embodiment of the present invention;

Figure 9 is a graph showing the increase in skin blood perfusion obtained in accordance with an embodiment of the present invention.

Detailed ways

Embodiments in accordance with the present invention provide a higher spectral density to the burst envelope, resulting in enhanced therapeutic efficacy on relevant dielectric pathways such as cell membrane receptors, ions bound to cellular enzymes, and generally transmembrane potential changes . Embodiments according to the invention increase the number of frequency components transmitted to relevant cellular pathways, thus providing access to a wider range of biophysical phenomena applicable to known healing mechanisms, such as the regulation of growth factors and cellular Factor release and ion binding at regulatory molecules. By applying a stochastic or other high spectral density envelope to the induction of a peak electric field between 10 ^-6 and 10 volts per centimeter (V/cm) according to a mathematical model defined by the SNR or power SNR within the transduction pathway A pulse train envelope of monopolar or bipolar rectangular or sinusoidal pulses to achieve greater effect on biological healing processes that can be applied to soft and hard tissues, thus enhancing the potency of pharmaceutical, chemical, cosmetic and topical agents.

An advantageous consequence of the present invention is the modulation of the power of the bursts for such amplitudes by applying a high spectral density voltage envelope as a modulation or burst definition parameter according to a mathematical model defined by the SNR or power SNR within the transduction pathway The requirements can be significantly lower than the power requirements of an unmodulated burst containing pulses in the same frequency range. Thus, the advantages of enhanced dosimetry of delivery to relevant dielectric target pathways and reduced power requirements are obtained.

Additional advantages of the present invention relate to enhancing the efficacy of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules by promoting the intended efficacy and enhancing the efficacy of said agents.

Time-varying currents from PEMF or PRF devices flow in target pathway structures such as molecules, cells, tissues, and organs, and these currents are a stimulus to which cells and tissues can respond in a physiologically meaningful manner. The electrical properties of the target pathway structure affect the level and distribution of induced currents. Molecules, cells, tissues, and organs all sense current pathways as cells within gap junction contacts. Ionic or ligand interactions at binding sites on macromolecules that may reside on membrane surfaces are voltage-dependent processes such as electrochemistry that may respond to induced electromagnetic fields (E). Induced currents reach these sites through the surrounding ionic medium. The presence of cells in the current pathway causes the induced current (J) to decay faster with time (J(t)). This is due to the increased electrical impedance of the cell from membrane capacitance and the time constant of association and other voltage sensitive membrane processes such as membrane transport.

Equivalent circuit models representing different membrane and charging interface configurations were derived. For example, in calcium (Ca ²⁺ ) binding, due to the induction E, the change in the concentration of bound Ca ²⁺ at the binding site can be described in the frequency domain by an impedance expression such as:

${\mathrm{<span\; class="notranslate">\; Z</span>}}_{\mathrm{<span\; class="notranslate">\; b</span>}}<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; \&omega;</span>}<span\; class="notranslate">\; )</span><span\; class="notranslate">\; =</span>{\mathrm{<span\; class="notranslate">\; R</span>}}_{\mathrm{<span\; class="notranslate">\; ion</span>}}<span\; class="notranslate">\; +</span>\frac{\mathrm{<span\; class="notranslate">\; 1</span>}}{\mathrm{<span\; class="notranslate">\; i\&omega;</span>}{\mathrm{<span\; class="notranslate">\; C</span>}}_{\mathrm{<span\; class="notranslate">\; ion</span>}}}$

It has the form of an equivalent circuit of a series resistor-capacitor. where ω is the angular frequency defined as 2πf, f is the frequency, i = -1 ^1/2 , Z _b (ω) is the binding impedance, and R _ion and C _ion are the equivalent binding resistance and capacitance of the ion binding pathway. The value of the equivalent binding time constant τ _ion = R _ion C _ion is related to the ion binding rate constant by τ _ion = R _ion C _ion = 1/k _b . Thus, the characteristic time constant of this pathway is determined by ion binding kinetics.

Induced E from PEMF or PRF signals can flow current into the ion-binding pathway and affect the number of Ca ²⁺ ions bound per unit time. Its electrical equivalent is the voltage change across the equivalent combined capacitance C _ion , which is a direct measurement of the charge change stored by C _ion . The charge is directly proportional to the surface concentration of Ca2 ⁺ ions within the binding site, ie, the storage of charge corresponds to the storage of ions or other charged species on cell surfaces and joints. Electrical impedance measurements and direct kinetic analysis of binding rate constants provide the time constant values necessary to configure the PMF waveform to match the bandpass of the target pathway structure. This allows for the required frequency range for any given induced E-waveform to optimally couple to a target impedance such as a bandpass.

Ions bound to regulatory molecules are common EMF targets, such as Ca2 ⁺ (CaM) bound to calmodulin. The use of this pathway is based on the promotion of tissue repair (eg, bone healing, wound healing, hair repair, and molecular, cellular, tissue and organ repair) that involves the regulation of growth factors released during different repair phases. Growth factors such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and epidermal growth factor (EGF) are all involved in the proper healing phase. Angiogenesis and neovascularization are also essential for tissue growth and repair and can be regulated by PMF. All of these factors are Ca/CaM dependent.

The Ca/CaM approach can be used to configure waveforms for which the induced power is substantially greater than the background thermal noise power. Under suitable physiological conditions, this waveform can have physiologically significant biological effects.

Application of the power SNR model to Ca/CaM requires knowledge of the electrical equivalent of ^Ca binding kinetics at CaM. Within the first-order binding kinetics, the time ^- dependent variation of the Ca concentration at the CaM binding site can be characterized in the frequency domain by the equivalent binding time constant τ _ion = R _ion C _ion , where R _ion and C _ion are equal Effective binding resistance and capacitance of ionic binding pathways. τ _ion is related to the ion binding rate constant k _b by τ _ion = R _ion C _ion = 1/k _b . Published values of _kb can then be used in cell array models to estimate SNR by comparing the voltage induced by the PRF signal with the thermal fluctuation of the voltage at the CaM binding site. Use the numerical values of the PMF response, such as V _max =6.5x10 ^-7 sec ^-1 , [Ca ²⁺ ] = 2.5 μM, K _D =30 μM, [Ca ²⁺ CaM] = K _D ([Ca ²⁺ ]+[CaM]), to obtain k _b =665sec ^-1 (τ _ion =1.5msec). Such τ _ion values can be used in the equivalent circuit for ion binding, and power SNR analysis can be performed for any waveform configuration.

According to embodiments of the present invention, a mathematical model, such as a mathematical equation and/or series of mathematical equations, may be configured to absorb thermal noise present in all voltage-dependent processes and represent minimum threshold requirements to establish adequate SNR. For example, a mathematical model expressing the minimum threshold requirement to establish a sufficient SNR can be configured to include the power spectral density of thermal noise, so the power spectral density of thermal noise S _n (ω) can be expressed as:

S _n (ω)=4kTRe[Z _M (x,ω)]

where Z _M (x, ω) is the electrical impedance of the target pathway structure, x is the dimensionality of the target pathway structure, and Re represents the real part of the impedance of the target pathway structure. Z _M (x, ω) can be expressed as:

${\mathrm{<span\; class="notranslate">\; Z</span>}}_{\mathrm{<span\; class="notranslate">\; m</span>}}<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; x</span>}<span\; class="notranslate">\; ,</span>\mathrm{<span\; class="notranslate">\; \&omega;</span>}<span\; class="notranslate">\; )</span><span\; class="notranslate">\; =</span><span\; class="notranslate">\; [</span>\frac{{\mathrm{<span\; class="notranslate">\; R</span>}}_{\mathrm{<span\; class="notranslate">\; e</span>}}<span\; class="notranslate">\; +</span>{\mathrm{<span\; class="notranslate">\; R</span>}}_{\mathrm{<span\; class="notranslate">\; i</span>}}<span\; class="notranslate">\; +</span>{\mathrm{<span\; class="notranslate">\; R</span>}}_{\mathrm{<span\; class="notranslate">\; g</span>}}}{\mathrm{<span\; class="notranslate">\; \&gamma;</span>}}<span\; class="notranslate">\; ]</span>\mathrm{<span\; class="notranslate">\; tanh</span>}<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; \&gamma;x</span>}<span\; class="notranslate">\; )</span>$

This equation clearly shows that the electrical impedance of the target pathway structure as well as contributions from the extracellular fluid resistance (Re), intracellular fluid resistance (Ri) and intermembrane resistance (Rg), which are electrically connected to the target pathway structure, all contribute to Noise filtering.

A general method of estimating SNR uses a single value of the root mean square (RMS) noise voltage. This was calculated by taking the square root of the integral of _Sn (ω)=4kTRe[ _ZM (x,ω)] over all frequencies related to the intact membrane response or to the bandwidth of the target pathway structure. SNR can be expressed as a ratio:

$\mathrm{<span\; class="notranslate">\; SNR</span>}<span\; class="notranslate">\; =</span>\frac{<span\; class="notranslate">\; |</span>{\mathrm{<span\; class="notranslate">\; V</span>}}_{\mathrm{<span\; class="notranslate">\; m</span>}}<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; \&omega;</span>}<span\; class="notranslate">\; )</span><span\; class="notranslate">\; |</span>}{\mathrm{<span\; class="notranslate">\; RMS</span>}}$

where |V _M (ω)| is the maximum magnitude of the voltage at each frequency when the selected frequency is delivered to the target pathway structure.

Embodiments of the present invention include pulse burst envelopes with high spectral density in order to enhance the therapeutic effect on relevant dielectric pathways such as cell membrane receptors, ions bound to cellular enzymes, and transmembrane potential changes in general. Thus, by increasing the number of frequency components transmitted to relevant cellular pathways, a wide range of biophysical phenomena applicable to known mechanisms of tissue growth (such as regulation of growth factor and cytokine release as well as ionic binding of regulatory molecules) is possible. Achieved. According to an embodiment of the invention, a random or other high spectral density envelope is applied to a burst envelope of a unipolar or bipolar rectangular or sinusoidal pulse that induces a peak electric field between about ^10-8 and about 100 volts V/cm , produces a greater effect on biological healing processes that can be applied to soft and hard tissues.

According to yet another embodiment of the present invention, by applying a high spectral density voltage envelope as a modulation or burst definition parameter, the power requirements for such amplitude modulated bursts can be significantly lower than those containing pulses in a similar frequency range. The power requirement of the unregulated burst. This is due to the fact that by imposing an irregular, preferably random amplitude on the otherwise substantially uniform burst envelope, a substantial reduction in the duty cycle within the repeating burst chain is produced. Thus, the dual advantages of enhanced dosimetry of transport to the relevant dielectric pathways and reduced power requirements are obtained.

1, wherein FIG. 1 is a flow diagram of a method according to an embodiment of the present invention for therapeutic and prophylactic purposes by delivering an electromagnetic signal that can be pulsed to target pathway structures (such as animals and humans) ions and ligands) to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents used to treat stem cells, tissues, cells, organs and molecules. Targeted pathway structures may also include, but are not limited to, stem cells, tissues, cells, organs, and molecules. Enhancing the efficacy of pharmaceutical, chemical, cosmetic, and topical agents includes, but is not limited to, increasing the rate of absorption, reducing actual dosage, accelerating the rate of delivery at the organismal level, and increasing the level of binding and transport kinetics at the molecular and cellular levels.

At least one active agent is applied to a target pathway structure (step 101). Active agents include, but are not limited to, pharmaceutical, chemical, cosmetic, topical, and genetic agents. The active agent may be administered orally, applied topically, applied intravenously, intramuscularly, or by any other means known in the medical arts to interact a substance with a target pathway structure, such as iontophoresis, X-radiation, and photoirradiation and heating. Agents include, but are not limited to, antibiotics, growth factors, chemotherapeutics, antihistamines, angiotensin inhibitors, beta-blockers, statins, and anti-inflammatory drugs. Chemical agents include, but are not limited to, hydrogen peroxide, betadine, and alcohol. Topical agents include, but are not limited to, antibiotics, creams, retinol, benzoyl peroxide, tolnaftate, menthol, emollients, oils, lanolin, squalene, aloe vera, antioxidants, fatty acids, Fatty acid esters, cod liver oil, alpha-tocopherol, petroleum, hydrogenated polybutene, vitamin A, vitamin E, topical protein and collagen. Cosmetic agents include, but are not limited to, cosmetics, eyelid inks, and rouges. Genetic agents include, but are not limited to, genes, DNA, and chromosomes.

At least one waveform having at least one waveform parameter is configured to couple to target pathway structures such as ions and ligands (step 102).

The at least one waveform parameter is selected to maximize at least one of a signal-to-noise ratio and a power signal-to-noise ratio in the target pathway structure such that the waveform in the target pathway structure is independent of background events such as fundamental voltage thermal fluctuations and in the target pathway structure. Electrically impedance detectable (step 102 ), background activity depends on the state of the cells and tissues, ie whether the state is at least one of resting, growing, replacing and responding to injury, to produce a physiologically beneficial outcome. To be detectable in a target pathway structure, the value of said at least one waveform parameter may be selected by using constants of said target pathway structure to estimate at least one of a signal-to-noise ratio and a power-to-signal-to-noise ratio for comparison by using constants of said target pathway structure in The voltage induced by the at least one waveform in the target pathway structure and the substantial thermal fluctuation and electrical impedance of the voltage in the target pathway structure, thereby by maximizing the in-bandpass in the target pathway structure At least one of said signal-to-noise ratio and power signal-to-noise ratio, by means of said at least one waveform, modulation of a biological effect occurs in said target pathway structure.

A preferred embodiment of the generated electromagnetic signal comprises a pulse train of an arbitrary waveform having at least one waveform parameter comprising a plurality of frequency components ranging from about 0.01 Hz to about 100 MHz, wherein the plurality of frequency components satisfy the power SNR Model (step 103). For example a repeating electromagnetic signal may be inductively or capacitively generated by the at least one waveform (step 104). Electromagnetic signals may also be non-repetitive. Electromagnetic signals are coupled to target pathway structures, such as ions and ligands, through the output of coupling devices, such as electrodes or inductors, placed in close proximity to the target pathway structure (step 105). Coupling of the electromagnetic signal to the target pathway structure may additionally occur, for example, at any time prior to application of the active agent, concurrently with application of the active agent, or after the time the active agent is applied. This coupling increases the regulation of blood flow and binding of ions and ligands to regulatory molecules in molecules, tissues, cells and organs, thus enhancing the biological efficacy of the active agent.

Figure 2 shows a preferred embodiment of the device according to the invention. The device is self-contained, lightweight and easily portable. A small control circuit 201 is coupled to at least one connector 202 such as one end of a wire, but the control circuit may also operate wirelessly. The opposite end of the at least one connector is coupled to a power generating device such as an electrical coil 203 . The small control circuit 201 is constructed by applying a mathematical model for configuring waveforms. The configured waveform must satisfy the power SNR such that, for a given and known target pathway structure, it is possible to select waveform parameters that satisfy the power SNR such that the waveform produces a physiologically beneficial outcome (e.g. modulation of biological effects) and is consistent with the target pathway structure. Intrinsic background activity is detectable. Preferred embodiments according to the invention apply mathematical models to induce time-varying magnetic fields and time-varying electric fields in target pathway structures (such as ions and ligands), including about 0.1 to about 100 pulses per second. Bursts of about 0.1 to about 100 milliseconds of 1 to about 100 microsecond rectangular pulses. The peak amplitude of the induced electric field is between about 1 μV/cm and about 100 mV/cm, varying according to a modified 1/f equation, where f=frequency. Waveforms configured to use according to preferred embodiments of the present invention may be applied to target pathway structures such as ions and ligands, preferably for a total irradiation time of 1 minute to 240 minutes per day. However, other irradiation times may be used. The waveform configured by the small control circuit 201 is guided to a power generating device 203 such as an electric coil through a connector 202 . The power generation device 203 delivers pulsed magnetic fields that can be used to provide therapy to target pathway structures, such as tissue. A small control circuit applies the pulsed magnetic field for a specified period of time and can automatically repeat the application of the pulsed magnetic field as many applications as desired within a given period of time (eg, 10 times a day). A small control circuit that applies pulsed magnetic fields in any time-repeating sequence can be configured to be programmable. According to a preferred embodiment of the present invention, the efficacy of pharmaceutical, chemical, cosmetic and topical agents can be enhanced by incorporation into a positioning device 204 such as a bed. Coupling pulsed magnetic fields to target pathway structures such as ions and ligands reduces inflammation in the treatment and prevention of disease, thereby advantageously reducing pain, promoting healing in the target site, and enhancing the efficacy of pharmaceuticals, chemicals, cosmetics, and topical Interaction of agents with target pathway structures. When an electrical coil is used as the power generating device 203, the electrical coil may be powered by a time-varying magnetic field that induces a time-varying electric field in the target pathway structure according to Faraday's law. Electromagnetic coupling may also be used to apply the electromagnetic signal generated by the power generation device 203, where the electrodes are in direct contact with the skin or an otherwise external electrically conductive boundary of the target pathway structure. Also in another embodiment according to the present invention electrostatic coupling can also be used to apply the electromagnetic signal generated by the generating device 203 where there is an air gap between the generating device 203 such as an electrode and the target pathway structure such as ions and ligands. An advantage of a preferred embodiment according to the present invention is that its ultra-light coils and miniaturized circuits allow for common physical therapy methods and for use wherever growth, pain relief and healing of tissues and organs is desired. An advantageous result of the application according to the preferred embodiments of the present invention is that tissue growth, repair and maintenance can be done and enhanced anywhere and at any time, for example while driving or watching TV. Yet another advantageous result of the application of the preferred embodiments is that the growth, repair and maintenance of molecules, cells, tissues and organs can be done and enhanced anywhere and at any time, such as while driving or watching TV.

FIG. 3 depicts a block diagram of a compact control circuit 300 according to a preferred embodiment of the present invention. A small control circuit 300 generates waveforms that drive a power generating device such as the metal coil described above in FIG. 2 . Small control circuits can be triggered by any triggering device such as an on/off type switch. The small control circuit 300 has a power source such as a lithium battery 301 . A preferred embodiment of the power supply has an output voltage of 3.3 volts, but other voltages may also be used. In another embodiment according to the present invention, the power source may be an external power source such as a current power outlet, such as an AC/DC power outlet coupled to the present invention by a plug and cord. The switching power supply 302 controls the voltage to the microcontroller 303 . A preferred embodiment of the microcontroller 303 uses an 8-bit 4 MHz microcontroller, but other bit MHz combination microcontrollers may be used. Switching power supply 302 may also deliver current to storage capacitor 304 . A preferred embodiment of the invention uses a storage capacitor with a 220 μF output, but other outputs can be used. Storage capacitor 304 allows high frequency pulses to be delivered to a coupling device such as an inductor (not shown). Microcontroller 303 also controls pulse shaper 305 and pulse phase timing control 306 . The pulse shaper 305 and pulse phase timing control 306 determine the pulse shape, burst width, burst envelope shape, and burst repetition rate. Integrating waveform generators such as sine waves or any number of generators can also be combined to provide specific waveforms. The voltage level translation subcircuit 307 controls the induction field delivered to the target pathway structure. Switch Hexfet 308 allows bursts of randomized amplitude to be passed to output 309 which sends the waveform to at least one coupling device such as an inductor. The microcontroller 303 can also control the total irradiation time of one treatment for target pathway structures such as molecules, cells, tissues and organs. The compact control circuit 300 can be configured to be programmable and apply the pulsed magnetic field for a specified period of time, and to automatically repeat the application of the pulsed magnetic field as many applications as desired within a given period of time (eg, 10 times a day). A treatment time of about 10 minutes to about 30 minutes is used according to a preferred embodiment of the invention.

Referring to Figures 4A and 4B, there is shown a coupling device 400 such as an inductor in accordance with a preferred embodiment of the present invention. The coupling device 400 may be an electrical coil 401 wound in a single or multi-strand flexible metal wire 402, however solid metal wire may also be used. In a preferred embodiment according to the invention, the metal wires are made of copper, but other materials may also be used. Multiple strands of flexible magnetic wire 402 enable electrical coil 401 to conform to specific anatomical structures such as human or animal limbs or joints. A preferred embodiment of the electrical coil 401 includes about 1 to about 1000 turns of at least one of a single-strand magnetic metal wire and a multi-strand magnetic metal wire having a diameter of about 0.01 mm to about 0.1 mm, and the wire is wound at a distance between about 2.5 cm and about 50 cm. The outer diameter between the structures is initially circular, but other numbers of turns and wire diameters may also be used. A preferred embodiment of the electrical coil 401 can be wrapped with a non-toxic PVC molding 403, but other non-toxic moldings can also be used. Electrical coils may also be incorporated into dressings, bandages, clothing, and other structures commonly used in wound treatment.

Referring to Figure 5, a waveform 500 according to an embodiment of the present invention is shown. The pulse 501 is repeated within a burst 502 of finite duration. Such a duration 503 is such that a duty cycle, which may be defined as the ratio of burst duration to signal period, is between about 1 and about 10 ⁻⁵ . A preferred embodiment in accordance with the present invention utilizes a quasi-rectangular 10 microsecond pulse as a pulse 501 for about 10 to about 50 milliseconds applied in a pulse train 502 having a modified 1/f amplitude envelope 504 with a value corresponding to about A finite duration 503 of burst periods between 0.1 and about 10 seconds, but other waveforms, envelopes and burst periods following mathematical models such as SNR and power SNR may be used.

Figure 6 shows a positioning device such as a wrist support according to a preferred embodiment of the present invention. A pointing device 600 , such as a wrist support 601 , is worn on a person's wrist 602 . The positioning device may be configured to be portable, may be configured to be disposable, or may be configured to be implantable. The positioning device can be used in conjunction with the present invention in a variety of ways, for example by incorporating the present invention into the positioning device, such as by Attaching the invention to a positioning device and holding the invention in place by configuring the positioning device to be resilient.

In another embodiment according to the invention, the invention can be configured as a stand-alone device of any size with or without a positioning device to be used anywhere such as at home, in a clinic, in a treatment center or outside. Wrist support 601 can be fabricated from any anatomical and support material such as neoprene. Coil 603 is incorporated into wrist support 601 such that a signal configured according to the present invention (such as the waveform depicted in FIG. 5 ) is applied from the dorsum at the top of the wrist to the metatarsus which is the bottom of the wrist. Use hardened equipment such as (not shown) microcircuits are attached to the outside of the wrist support 601 . The microcircuit is coupled to one end of at least one connection device such as a flexible wire 605 . The other end of the at least one connection device is coupled to the coil 603 . Positioning devices according to other embodiments of the invention include knees, elbows, lower backs, shoulders, other anatomical wrappings, and articles of clothing such as clothing, fashion accessories, and footwear.

Referring to Figure 7, an electromagnetic therapy device incorporated into a mattress pad 700 is shown, in accordance with an embodiment of the present invention. Mattresses are also available. Several lightweight flexible coils 701 are incorporated into the mattress pad. Lightweight flexible coil 701 may be constructed of thin flexible conductive metal wires, conductive filaments, and any other flexible conductive material. The flexible coil is connected to at least one end of at least one metal wire 702 . However, the flexible coil can also be configured to connect directly to the circuit 703 or wirelessly. A lightweight miniaturized circuit 703 configured in a waveform according to an embodiment of the present invention is connected to at least the other end of the at least one metal line. When the lightweight miniaturized circuit 703 is triggered, a waveform directed to the flexible coil (701 ) is configured to generate a PEMF signal coupled to the target pathway structure.

Example 1

Embodiments according to the invention for EMF signaling configuration are used for calcium-dependent myosin phosphorylation in standard enzyme assays. This enzymatic pathway is known to enhance the efficacy of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules. The reaction mixture was chosen so that the phosphorylation rate was linear over a period of several minutes and for a sub-saturating Ca2 ⁺ concentration. This opens up biological potential for EMF-sensitive Ca ²⁺ /CaM when occurring in an injury or due to the application of pharmaceutical, chemical, cosmetic and topical agents applied to human, animal and plant cells, organs, tissues and molecules. window. Experiments were performed using myosin light chain (MLC) and myosin light chain kinase (MLCK) isolated from turkey gizzard. The reaction mixture mainly consisted of the following: base solution containing 40 mM Hepes buffer solution, pH 7.0; 0.5 mM ammonium acetate; 1 mg/ml bovine serum albumin, 0.1% (w/v) Tween 80; and 1 mM EGTA. Free Ca2 ⁺ varied in the range of 1-7 μM. Once the Ca ²⁺ buffer was established, freshly prepared 7OnM CaM, 16OnM MLC and 2nM MLCK were added to the base solution to form the final reaction mixture.

Reaction mixtures were prepared fresh daily for each series of experiments and aliquoted into 100 μL aliquots into 1.5 ml Eppendorf tubes. All Eppendorf tubes containing the reaction mixture were maintained at 0°C and then transferred to a specially designed water bath maintained at 37±0.1°C by continuous perfusion of water preheated through a Fisher Scientific Model 900 heat exchanger. Temperature was monitored using a thermistor probe (eg, Cole-Parmer model 8110-20) submerged in an Eppendorf tube during all experiments. Reactions were started with 2.5 μM 32P ATP and stopped with Laemmli sample buffer solution containing 30 μM EDTA. A minimum of five blank samples was counted in each experiment. Blanks consisted of the entire assay mixture minus one of the active ingredients Ca ²⁺ , CaM, MLC or MLCK. Phosphorylation was allowed to proceed for 5 minutes and estimated by ^counting32P integrated in the MLC using a TM analysis model 5303 Mark V liquid scintillation counter.

The signal consists of repetitive bursts of high-frequency waveforms. The amplitude was held constant at 0.2G and the repetition rate was 1 burst/sec for all irradiations. Burst durations vary from 65 to 1000 sec according to estimates from the mathematical analysis of the present invention showing that the best power SNR is obtained when the burst duration approaches 500 sec. The results are shown in Figure 8, where burst width in μsec 801 is plotted on the x-axis and myosin phosphorylation 802 as treated/sham is plotted on the y-axis. It can be seen that the effect of PMF on Ca ²⁺ binding to CaM is close to its maximum at about 500 μsec, exactly as indicated by the power SNR model.

These results confirm that for burst durations sufficient to obtain optimal power SNR for a given magnetic field magnitude, EFM signals configured according to embodiments of the present invention will maximize the and Molecular Pharmacy, Chemical, Cosmetic and Topical agents.

Example 2

This study determined to what extent treatment with pulsed electromagnetic frequency (PEMF) waveforms affected blood perfusion in the treated site. All tests were performed in a temperature-controlled room (23 to 24°C) with the patient in a comfortable chair. On each arm, a non-metallic laser Doppler probe was secured with double-sided tape to the mid-forearm approximately 5 cm away from the cubital fossa. A temperature-sensing thermistor for surface temperature measurement was placed approximately 1 cm away from the outer edge of the probe and secured with tape. A towel was draped over each forearm to reduce the direct impact of any moving air currents. The patient rests comfortably and the skin temperature of each arm is monitored. During this monitored time interval, the excitation coil used to generate the PEMF waveform according to the present invention was positioned directly above the laser Doppler detector on the right forearm at a vertical distance of approximately 2 cm from the skin surface. The data acquisition phase begins when the monitored skin temperature reaches a steady-state value. This mainly consisted of 20 min basic time intervals followed by 45 min time intervals, in which the PEMF waveform was applied.

Skin temperature was recorded at 5 min intervals throughout the procedure. The blood perfusion signal determined with a laser Doppler flowmeter (LDF) is continuously displayed on a chart recorder and simultaneously obtained by a computer following analog-to-digital conversion. The LDF signal was time-averaged by computer during each successive 5-minute measurement interval to generate a signal-averaged perfusion value for each interval. At the end of the procedure, the relative magnetic field strength is measured at the skin site with a 1 cm diameter ring coupled to a specially designed and calibrated metrology system.

For each patient, basal perfusion for the treatment and control arms was determined as the mean value during a 20-minute basal time interval. Following initiation of PEMF treatment, subsequent perfusion values are expressed as a percentage of this baseline. Comparisons between treatment and counter arms were performed using analysis of variance, with arm as the grouping variable (treatment vs. control) and time as a repeated measure.

FIG. 9 summarizes the time course of changes in perfusion observed during treatment for nine patients, with time plotted on the x-axis 901 and perfusion plotted on the y-axis 902 . Analysis revealed a significant treatment-time interaction (P=0.03), with blood perfusion significantly (P<.01 ) increased in the treated arm after 40 minutes of PEMF treatment. The absolute value (mv) of basal perfusion did not differ between the control and treatment arms. Analysis of covariance with basal perfusion in absolute units (mv) as covariance also showed overall differences between treatment and control arms (P<.01).

The main finding of this investigative study is that PEMF treatment, when applied in the manner described, is associated with a significant increase in microvascular perfusion in resting forearm skin. This increase of about 30% on average occurred after about 40 minutes of treatment when compared to resting pre-treatment levels, but there was no such significant increase in the contralateral non-treated arm. This allows for increased flux of pharmaceutical, chemical, cosmetic and topical agents to the intended tissue target.

Embodiments of devices and methods for enhancing pharmacological effects are described, noting that modifications and variations may be made by those skilled in the art in light of the above teachings. It is therefore to be understood that changes in the particular embodiments of the invention disclosed are within the scope and spirit of the invention as defined by the appended claims.

Claims (41)

1. method that is used to strengthen pharmacological action, it comprises step:

At least a activating agent is applied to the target pathway structure;

At least one waveform that configuration has at least one waveform parameter;

Select the value of described at least one waveform parameter of described at least one waveform, in the applied target pathway structure of described activating agent, to maximize in signal to noise ratio and the PSNR power signal-to-noise ratio at least one;

Use maximizes in described signal to noise ratio and the PSNR power signal-to-noise ratio described at least one waveform of at least one in the target pathway structure, to produce electromagnetic signal; With

Described electromagnetic signal is coupled to described target pathway structure to regulate described target pathway structure.

2. the method for claim 1, that the step of at least a activating agent of wherein said application comprises is oral, in intravenous injection, intramuscular injection and the topical application at least one.

3. the method for claim 1, wherein said activating agent comprises in medicament, chemical agent, local agent, enamel and the genetic agents at least one.

4. the method for claim 1, wherein said at least one waveform parameter comprises at least one following parameter: with multiple frequency component parameter between described at least one contoured configuration Cheng Zaiyue 0.01Hz and the about 100MHZ, follow the impulse train amplitude envelops parameter of the amplitude function that on mathematics, defines, the burst width parameter that changes at each place of repetition according to the width function that defines on the mathematics, the peak induction electric pulse field parameter that in described target pathway structure, between about 1 μ V/cm and about 100mV/cm, changes according to the function that defines on the mathematics, and the peak induction magnetoelectricity field that in described target pathway structure, between about 1 μ T and about 0.1T, changes according to the function that defines on the mathematics.

5. method as claimed in claim 4, the amplitude function of wherein said definition comprise in 1/f frequency function, logarithmic function, chaotic function and the exponential function at least one.

6. the method for claim 1, wherein said target pathway structure comprises in stem cell, molecule, cell, tissue, organ, ion and the part at least one.

7. the method for claim 1, it further comprises ion and part are combined step with the effectiveness that strengthens described activating agent with the adjusting molecule.

8. method as claimed in claim 7, the bonded step of wherein said ion and part comprise regulates combining of calcium and calmodulin, CaM.

9. method as claimed in claim 7, the bonded step of wherein said ion and part comprise the generation of regulating somatomedin in the target pathway structure.

10. method as claimed in claim 7, the bonded step of wherein said ion and part comprise regulates production of cytokines in the target pathway structure.

11. method as claimed in claim 7, the bonded step of wherein said ion and part comprises somatomedin and the cytokine that adjusting is relevant with tissue growth, reparation and maintenance.

12. comprising, method as claimed in claim 7, the bonded step of wherein said ion and part regulate angiogenesis and neovascularization, to strengthen the effectiveness of described activating agent in described target pathway structure.

13. the method for claim 1, it comprises that further application standard naturopathy method strengthens the step of the effectiveness of described activating agent.

14. method as claimed in claim 13, wherein the standard physical Therapeutic Method comprises in heating, cooling, compressing, massage and the exercise at least one.

15. the method for claim 1, it comprises that further increasing ion and part transports step with the effectiveness that strengthens described activating agent to the extracellular of regulating molecule.

16. the method for claim 1, it further comprises increases ion and part to the transmembrane transport of the adjusting molecule step with the effectiveness that strengthens described activating agent.

17. the method for claim 1, the step of the described electromagnetic signal of wherein said coupling comprise additional coupling.

18. the method for claim 1, it further comprises the step of application standard therapeutic treatment with the effectiveness that strengthens described activating agent.

19. method as claimed in claim 18, wherein the standard medical treatment comprises in tissue transplantation and the organ transplantation at least one.

20. an electromagnetic treatment apparatus that is used to strengthen pharmacological action, it comprises:

Waveform generating apparatus, its generation have at least one waveform of at least one waveform parameter, described at least one waveform parameter can be selected to the interactional target pathway structure of activating agent in maximization signal to noise ratio and the PSNR power signal-to-noise ratio at least one; With

Be connected to the Coupling device of described Waveform generating apparatus, it is used for from least one described at least one waveform generation electromagnetic signal described target pathway structure described signal to noise ratio of maximization and PSNR power signal-to-noise ratio, and be used for described electromagnetic signal is coupled to described target pathway structure, thereby regulate described target pathway structure.

21. electromagnetic treatment apparatus as claimed in claim 20, wherein said at least one waveform parameter comprises at least one following parameter: described at least one contoured configuration is become according to mathematical function multiple frequency component parameter between about 0.01Hz and about 100MHZ, follow the impulse train amplitude envelops parameter of the amplitude function that on mathematics, defines, the burst width parameter that changes at each place of repetition according to the width function that defines on the mathematics, the peak induction electric pulse field parameter that in described target pathway structure, between about 1 μ V/cm and about 100mV/cm, changes according to the function that defines on the mathematics, and the peak induction magnetoelectricity field parameter that in described target pathway structure, between about 1 μ T and about 0.1T, changes according to the function that defines on the mathematics.

22. electromagnetic treatment apparatus as claimed in claim 21, the amplitude function of wherein said definition comprise in 1/f frequency function, logarithmic function, chaotic function and the exponential function at least one.

23. electromagnetic treatment apparatus as claimed in claim 20, wherein said target pathway structure comprises in stem cell, molecule, cell, tissue, organ, ion and the part at least one.

24. electromagnetic treatment apparatus as claimed in claim 20, wherein said activating agent comprise in medicament, chemical agent, local agent, enamel and the genetic agents at least one.

25. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device comprise in active Coupling device, inductive coupled device, Capacitance Coupled equipment and the biochemistry Coupling device at least one.

26. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, to regulate combining of calcium and calmodulin, CaM, strengthens the effectiveness of described activating agent.

27. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, to regulate in somatomedin generation relevant with the effectiveness that strengthens described activating agent and the cytokine generation at least one.

28. electromagnetic treatment apparatus as claimed in claim 27, wherein said somatomedin comprise in fibroblast growth factor, platelet derived growth factor, interleukin somatomedin and the bone morphogenetic protein somatomedin at least one.

29. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, to regulate angiogenesis and neovascularization, strengthens the effectiveness of described activating agent.

30. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, with the generation of mediator's somatomedin, strengthens the effectiveness of described activating agent.

31. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, to increase cell and tissue activity, strengthens the effectiveness of described activating agent.

32. electromagnetic treatment apparatus as claimed in claim 20, wherein said Coupling device is coupled to described target pathway structure with described signal, to increase cell mass, strengthens the effectiveness of described activating agent.

33. electromagnetic treatment apparatus as claimed in claim 20, wherein said Waveform generating apparatus, connecting device and Coupling device are configured to light-duty and portative.

34. electromagnetic treatment apparatus as claimed in claim 20, wherein said Waveform generating apparatus, connecting device and Coupling device merge in mattress, mattress cushion, bed and the positioning equipment at least one.

35. comprising, electromagnetic treatment apparatus as claimed in claim 34, wherein said positioning equipment dissect in support, dissection wrappage and the medicated clothing at least one.

36. electromagnetic treatment apparatus as claimed in claim 35, wherein said medicated clothing comprise in clothes, fashion accessory and the footgear at least one.

37. electromagnetic treatment apparatus as claimed in claim 20, wherein said Waveform generating apparatus is programmable.

38. electromagnetic treatment apparatus as claimed in claim 20, wherein said Waveform generating apparatus transmit at least one pulsed magnetic signal during preset time.

39. electromagnetic treatment apparatus as claimed in claim 20, wherein said Waveform generating apparatus transmits at least one pulsed magnetic signal at time durations at random.

40. electromagnetic treatment apparatus as claimed in claim 20, it further comprises the transfer device that is used for the standard physical Therapeutic Method.

41. electromagnetic treatment apparatus as claimed in claim 40, wherein said standard physical Therapeutic Method comprise in heating, cooling, massage and the exercise at least one.

Images